drugset
drugset / Trial / NCT04787302

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

NCT04787302 ↗

Phase 1 Completed 15 enrolled Cerevel Therapeutics, LLC
NaSingle-groupOpen-labelBasic science

Summary

PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing

Timeline

Start
2021-06-01
Primary completion
2023-07-14
Completion
2023-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Emraclidine Small molecule 30 mg Oral

Indications

schizophrenia